rs3816873 — MTTP MTTP I128T

MTTP I128T — A Missense Variant That Reshapes Lipid Export from the Liver

Your liver is a lipid logistics hub. Every gram of fat synthesized from excess carbohydrate, every fatty acid rescued from circulation, every dietary fat re-exported after absorption — all of it leaves the liver packaged into VLDL particles¹¹ VLDL particles
Very-low-density lipoprotein: triglyceride-rich particles assembled in the liver and secreted into blood, where they deliver fat to peripheral tissues. The enzyme responsible for loading triglycerides into those particles is MTTP — microsomal triglyceride transfer protein²² MTTP — microsomal triglyceride transfer protein
MTTP transfers triglycerides, phospholipids, and cholesteryl esters onto nascent apolipoprotein B during VLDL assembly in the liver and chylomicron assembly in the intestine. Without functional MTTP, VLDL cannot be assembled, triglycerides accumulate in hepatocytes, and plasma lipid levels fall sharply — the phenotype of abetalipoproteinemia, a rare recessive disorder caused by null MTTP mutations.

The I128T variant (rs3816873) substitutes isoleucine for threonine at position 128 of the MTTP protein. It is common — the Thr128 (C) allele occurs in about 25% of Europeans and 34% of South Asians — yet it was classified as benign for years, its metabolic effects dismissed as too modest to matter. That view has changed.

The Mechanism

Isoleucine at position 128³³ Isoleucine at position 128
A nonpolar, branched-chain amino acid embedded in the hydrophobic core of the MTTP N-terminal domain sits in a region of MTTP critical for its lipid-transfer scaffold. The Ile→Thr substitution⁴⁴ Ile→Thr substitution
Threonine is polar and hydroxyl-bearing; replacing a hydrophobic residue with a polar one at this position likely alters the protein's local conformational dynamics changes the physicochemical character of this site — polar threonine where non-polar isoleucine once held structure. This does not abolish MTTP activity (as null mutations do in abetalipoproteinemia), but it appears to subtly reconfigure how efficiently MTTP loads triglycerides onto nascent VLDL particles. A 2023 study in 489,000+ participants concluded the I128T variant is "neither a classic loss nor gain of function allele," pointing to a more nuanced alteration of MTP lipid-transfer dynamics that simultaneously reduces hepatic fat retention and plasma lipid levels.

The Evidence

The strongest evidence comes from a large biobank study⁵⁵ large biobank study
Schneider et al. 2023, Penn Medicine Biobank (n=37,960) and UK Biobank (n=451,444), examining 24 MTTP missense variants. Carriers of the Thr128 (C) allele showed reduced hepatic steatosis on imaging, fewer biopsy-proven steatosis cases, and lower plasma LDL-cholesterol and apoB concentrations (all p<0.001). The scale of this study makes confounding unlikely.

Smaller studies give a more complex picture. A 2011 Iranian case-control study⁶⁶ 2011 Iranian case-control study
Hashemi et al., 83 NAFLD cases vs. 93 controls, DNA Cell Biol found the CT genotype had an OR of 2.467 (95% CI 1.253–4.854) for NAFLD — a risk direction opposite to the biobank data. However, a 2020 meta-analysis of 10 case-control studies⁷⁷ 2020 meta-analysis of 10 case-control studies
Tan et al., 1,388 NAFLD cases and 1,690 controls, Saudi J Gastroenterol found no significant overall association (OR 1.23, 95% CI 0.76–2.01, p=0.398), implying the small-study positive findings likely reflect population stratification or underpowering. In the context of viral hepatitis, the variant showed a strong interaction effect: Prata et al. 2022⁸⁸ Prata et al. 2022
236 chronic hepatitis C patients, Clinics São Paulo found the I128T allele combined with HCV genotype 3 produced an 8.5-fold elevated steatosis risk — a clinically important gene-virus interaction.

For plasma lipids, evidence from a large German cohort⁹⁹ large German cohort
Böhme et al. 2008, KORA study, n=7,582, Mol Genet Metab found MTTP variants modulated lipid homeostasis, with sex-specific effects. For Korean patients with alcoholic liver disease, the wild-type Ile128 (T allele)¹⁰¹⁰ wild-type Ile128 (T allele)
Jun et al. 2009, Eur J Gastroenterol Hepatol was more prevalent in those with fatty liver, and I/I carriers showed significantly elevated ALT — consistent with the C allele (Thr128) being protective in the context of alcohol-related hepatic stress.

Practical Actions

The Thr128 C allele is associated with modestly better lipid export efficiency and reduced hepatic fat accumulation at population scale. Homozygous C;C carriers may have a metabolic advantage in terms of VLDL assembly, translating to lower LDL-C and apoB, which directly reduces cardiovascular disease risk.

Wild-type T;T homozygotes carry the ancestrally common form (Ile128) and appear to have a slightly less efficient lipid export phenotype — their hepatic fat risk is not dramatic but warrants awareness, particularly in the context of high dietary saturated fat intake or alcohol use, both of which impose hepatic triglyceride loading that depends on efficient VLDL secretion via MTTP.

Heterozygous C;T carriers fall between these two extremes, with one copy of the efficiency-altering allele.

Interactions

The most clinically documented interaction is with HCV genotype 3 infection: I128T carriers with this viral strain show dramatically elevated hepatic steatosis risk (OR ~8.5), suggesting the variant's effect on MTTP function is exacerbated by HCV-driven lipid dysregulation. This is a gene-virus interaction rather than a gene-gene interaction in the traditional sense.

For gene-gene interactions, MTTP function interacts with APOE genotype (which governs apolipoprotein B receptor-mediated clearance), PCSK9 variants (which modulate LDL receptor density), and PNPLA3 rs738409 (a well-replicated NAFLD risk variant in a different pathway — hepatic triglyceride hydrolysis). T;T carriers who also carry PNPLA3 GG or APOE ε4 may face compounding hepatic lipid stress from impaired export (MTTP) and impaired hydrolysis (PNPLA3) or elevated apoB production (APOE).